home > news > detailed info

Norwich Pharmaceuticals Announces Significant Business Growth

Norwich Clinical Services

Increased project volume, new clients propel revenues and expanded services

Norwich Pharmaceuticals, a provider of full-service contract development and manufacturing services for the pharmaceutical and biotech industry, announced today that the company has achieved significant business growth in first quarter, 2012 as compared to the same period in 2011. Key growth areas include volume of projects currently in development and commercial production, scope of projects expanded into multiple service categories, and total value of new business won.

"Norwich’s growth is a direct result of our ability to maintain high quality standards while providing expertise and flexibility for both product development and commercial manufacturing," said Terry Novak, president of Norwich. "During the past year, Norwich has expanded our capabilities to meet the market demands for smaller scale development services. Providing expertise in novel, solid dose formulations, we have been able to offer services to new clientele while increasing our repeat business rate with current customers."

New client awards in the first quarter accounted for 33% of all Norwich projects while repeat business in Q1, 2012 more than doubled as compared to the same period last year. The total value of new projects increased 25%. Several of the new projects will utilize Norwich services for potent compounds, low humidity, bead extrusion, tablet coating, formulation development, BA/BE studies, and global packaging and distribution.

About Norwich Pharmaceuticals

Norwich is a full-service contract development and manufacturing provider for Rx and OTC pharmaceuticals. Norwich applies more than 120 years of experience and an unparalleled compliance record to offer customers greater flexibility, resources and speed that result in a streamlined progression from product development to scale-up and commercial manufacturing through clinical services. Visit for more information.

phone +1 888 674 7979
email 6826 State Highway 12, Norwich, NY 13815, UNITED STATES
Print this page
Send to a friend
News and Press Releases

Cancer Research UK and Linguamatics Collaborate to Improve Characterisation of Cancer Patient Data for Precision Medicine

Linguamatics I2E natural language processing technology to automatically extract clinical attributes from pathology reports across eight hospital groups in Stratified Medicine Programme.
More info >>

White Papers

pAVEway™ expression system for the efficient expression of therapeutic proteins

Fujifilm Diosynth Biotechnologies

One of the major bottlenecks in the production of biopharmaceuticals is the efficient expression of therapeutic proteins in microbial or mammalian cells. The Escherichia coli pAVEway™ expression system described here has been developed to ensure high product titres and efficient scale up to GMP manufacture, whilst minimising many common issues seen in other expression systems, such as ‘leaky’ expression (expression of recombinant protein in the absence of inducer).
More info >>

Industry Events

The Pharmaceutical and Medical Device Labelling Summit

27-28 October 2015, Maritim proArte Hotel Berlin

Optimise Your Labelling Strategies to Ensure Accurate Product Information and Successful Regulatory Compliance. 1 Event, 2 Streams. Join us in Berlin this October to benefit from industry leaders providing their experience and expertise within this complex and ever-changing landscape.
More info >>

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement